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Philipp T. Meyer, MD,|| and Constantin Lapa, MD†Purpose: PET/CT using O-(2-[18F]fluoroethyl)-L-tyrosine (18F-FET) has
proven valuable in differentiating tumor recurrence and progression from
therapy-induced changes. This study aimed to investigate the diagnostic per-
formance of several analytic approaches in the setting of suspected late
pseudoprogression (PsP) in glioblastoma multiforme (GBM).
Methods: Retrospective analysis of tumor recurrence was performed in
36 patients with histopathologically confirmed GBM and suspicion of
recurrence/disease progressionmore than 12weeks from cessation of irradiation
based on MRI and Response Assessment in Neuro-Oncology working group
criteria. For differentiation of late PsP from true tumor recurrence, images were
analyzed semiquantitatively employing tumor-to-brain ratios using 5 different
approaches for tumor and normal brain reference region definition, respectively.
Histopathology and/or clinical and imaging follow-up served as reference. Re-
spective areas under the receiver operating characteristic curve were compared.
Results: 18F-FET PETwas able to reliably differentiate PsP from true tumor
progression with areas under the receiver operating characteristic curve rang-
ing from 0.80 to 0.88 (all P < 0.01). Irrespective of the approach chosen, the
classification differences between the applied methods were not significant
(all P > 0.05), albeit approaches focusing on voxels with the highest uptake
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Clinical Nuclear Medicine • Volume 44, Number 9, September 20Conclusions: Irrespective of the analytical approach, 18F-FET PET is a ro-
bust tool for detection of late PsP with only minor differences between dif-
ferent analytical approaches. However, methodological standardization and
harmonization are needed to ensure comparability between different centers.
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P ET using O-(2-[18F]fluoroethyl)-L-tyrosine (18F-FET) as amarker of amino acid transport is an established tool in brain
tumor imaging, including grading,1–3 delineation of tumor extent,4
biopsy guidance,5,6 prognostication,7–9 treatment monitoring,10–12
and differentiation of nonspecific posttherapeutic changes from
tumor recurrence.13–15
In daily routine, differentiation of viable tumor from treatment-
related changes is predominantly established by determination of
tracer uptake of both the tumor and normal brain tissue and subse-
quent calculation of tumor-to-brain ratios (TBRs). However, various
approaches for deriving the respective values have been published
in the literature, hampering comparability of data between different
studies and sites.16,17 Given the need for prospective multicenter tri-
als (eg, to strengthen clinical evidence for the utility of PET-based im-
aging in glioma or for use of 18F-FET for treatment decisions and
planning18), a well-founded selection of the most accurate approach
and subsequent methodological standardization is of high relevance.
As a first step in this direction, the aim of the present study
was to assess the diagnostic performance of several analytic ap-
proaches in the setting of suspected late pseudoprogression (PsP)
in glioblastoma multiforme (GBM).MATERIALS AND METHODS
Subjects
This retrospective analysis was performed using data from a
previously published cohort of 36 patients (22 males and 14 fe-
males; aged 24–75 years; mean age, 54 ± 14 years) with histopath-
ologically confirmed GBM. All patients were referred to 18F-FET
PET/CT because of MRI-based suspicion of recurrence/disease
progression, as determined by the Response Assessment in
Neuro-Oncology (RANO) working group criteria.14 Patients were
identified consecutively and selected according to the initial scan
date, which ranged from April 2010 to August 2016. The interval
between cessation of radiation therapy and subsequent PET imaging
was more than 12 weeks in all cases. The local ethics committee of
the University of Würzburg approved this retrospective analysis of
routinely acquired data.19 www.nuclearmed.com 695
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Synthesis of 18F-FETwas performed in-house at the University
Hospital of Würzburg with methods previously described,19 using a
GE TRACERlab FX-FN synthesis module (GE Medical Systems,
Uppsala, Sweden).
All patients fasted for at least 12 hours before PET imaging.20
Twentyminutes after intravenous injection of 18F-FET (217 ± 13MBq),
the patients were scanned using an integrated PET/CT scanner
(Biograph mCT 64; Siemens Healthineers, Knoxville, Tenn). PET
emission data were collected in 3-dimensional mode using a
200  200 matrix for 10 minutes.
Subsequent CT scans for attenuation correction were ac-
quired using a low-dose protocol (CARE Dose 4D; 80 mAs;
120 kV; matrix, 512  512; 3-mm slice thickness; increment,
30 mm/s; rotation time, 0.5 second; pitch index, 0.8). PET images
were reconstructed iteratively (TrueX; 3 iterations; 24 subsets;
Gaussian filtering, 2 mm; decay, attenuation, and scatter correction)
using dedicated manufacturer software (syngo MI.PET/CT;
Siemens Healthineers).
Image Analysis
Tumor-to-brain ratios were determined according to 4 previ-
ously described13,14,21,22 and additionally proposed semiquantita-
tive analysis methods. Irrespective of the approach, the transaxial
slicewith the highest amino acid uptakewas chosen for further anal-
ysis. SUVs of both the tumor and normal brain tissue, as well as re-
spective TBR, were determined as follows:
1) Kebir et al13 first selected the transaxial slice with the highest
tracer accumulation of the tumor. Next, normal brain uptake
was determined by a region of interest (ROI) of 50-mm diam-
eter placed on the contralateral hemisphere in an area of
normal-appearing brain tissue including white and gray mat-
ter.20 SUVmean of the tumor was defined by a 2-dimensional
autocontouring process using a TBR of at least 1.6. For tumorTABLE 1. Overview of Region Definitions Used for the Different An
Tumor Region (Target)
Kebir et al13 SUV16mm: Mean uptake within a circular ROI of
16-mm diameter centered on the voxel with
maximal tumor uptake
SUVmean
1 : Isocontour ROI applied to the transax
slice with maximum tumor uptake including all
voxels exceeding a predefined TBR of >1.6
Rapp et al22 SUVmax
2 : Voxel with maximum uptake
SUVmean
1 : Isocontour ROI applied to the transax
with maximum tumor uptake including all
voxels exceeding a predefined TBR of >1.6
Mihovilovic et al14 SUVmax
2 : Voxel with maximum uptake
SUV10mm: Circular ROI of 10-mm diameter
centered on voxel with maximal tumor
Pöpperl et al21 SUVmax: Voxel with maximum uptake
SUV70% and SUV80%: 70% and 80% isocontou
ROIs applied to the transaxial slice
with maximum tumor uptake, respectively
“Crescent shaped” SUVmax: Voxel with maximum uptake
SUVmean: Isocontour ROI applied to the transax
slice with maximum tumor uptake including all
voxels exceeding a predefined TBR of >1.6
SUV90%: 90% isocontour ROI applied to the
transaxial slice with maximum tumor uptake
Superscripts 1 and 2 denote pairs of identical analytical approaches.
696 www.nuclearmed.comareas with the highest uptake (SUV16mm), a circular ROI with
a diameter of 16 mm was centered on maximal tumor uptake.
Mean TBR and maximum TBR (TBRmean and TBR16mm)
were calculated by dividing the SUVmean within these 2 tumor
ROIs by the SUVmean of normal brain.13
2) Rapp et al22 used an approach similar to (1), with the only
difference of SUVmax being the voxel with the highest
amino acid uptake.22
3) Mihovilovic et al14 determined SUVmax as the voxel with the
maximum tracer uptake and SUV10mm as the SUVmean in an
ROIwith 10-mmdiameter centered on this voxel. For derivation
of TBRmax and TBR10mm, a second region with 50-mm diam-
eter including white and gray matter was selected in an area of
normal-appearing brain tissue on the contralateral hemisphere
of the same slice.14
4) Pöpperl et al21 calculated the tumor SUVmax by using the voxel
with the maximum FETuptake. In the same slice, the SUVmean
within 80% and 70% isocontour ROIs was assessed (SUV80%
and SUV70%, respectively). For TBR calculation, the background
uptake was derived from the mean of the 70% and 80%
isocontour ROIs mirrored to the contralateral hemisphere.21
5) The use of a crescent-shaped region for assessment of normal
brain uptake is used in clinical routine at some centers (see also
Unterrainer et al16). We further refined this approach (“cres-
cent shaped”) by using a crescent-shaped volume of interest
(VOI) (composed of 3 ROIs) positioned on 3 transaxial slices
on the level of the basal ganglia (striatum/capsula interna).
The ROIs include cortical and subcortical gray and white matter
by delineating the outer rim of the cortex from frontal to occip-
ital and the inner cortical to subcortical interface at the depth of
the sulci and the capsula interna, so that the putamen is included.
Furthermore, the ventricles aswell as enlarged outer cerebrospinal
fluid spaces or possible structural lesions (eg, infarctions, al-
though not present in the current sample) are carefully excluded.
Tumor SUVmean and SUVmaxwere calculated as defined byRappalytical Approaches
Normal Brain Region (Reference)
ial
ROI of 50-mm diameter placed on the
contralateral hemisphere including
white and gray matter
ial slice
ROI of 50-mm diameter placed on the
contralateral hemisphere including
white and gray matter
ROI of 50-mm diameter placed on
the contralateral hemisphere including
white and gray matter
r
Mean value of the 70% and 80% isocontour
ROIs mirrored onto the contralateral hemisphere
ial
Mean value of 3 crescent-shaped ROIs positioned
over the contralateral hemisphere on the
level of the basal ganglia
© 2019 The Author(s). Published by Wolters Kluwer Health, Inc.
Clinical Nuclear Medicine • Volume 44, Number 9, September 2019 Different FET PET Approaches in Late PsPet al.22 In addition, we used a 90% isocontour covering the
lesion on the transaxial slice with the highest uptake (SUV90%).
Table 1 and Figure 1 provide an illustration of the various
analytic approaches.
Diagnosis of True Progression
Diagnosis of true tumor progression was based on histopatho-
logic proof, clinical deterioration, and/or further radiological progres-
sion in a follow-upMRI at least 4 weeks after the initial assessment.23
Histopathologic diagnosis of tumor recurrence was estab-
lished according to standard morphologic criteria including detec-
tion of highly cellular areas composed of pleomorphic tumor cells
with nuclear atypia and brisk mitotic activity as well as prominent
microvascular proliferation and palisading necrosis as supporting
but not mandatory criteria.
In cases without solid GBMmanifestations, criteria to distin-
guish between true progression and PsP included higher cellularity
compared with normal brain tissue, presence of cellular pleomor-
phism, nuclear atypia and mitoses, and elevated proliferation index
(Ki67) and p53 nuclear expression in glial cells (glial fibrillary
acidic protein). The density of macrophages (CD68) as potential
confounder of proliferation index was also assessed.
In contrast, the diagnosis of PsP was applied in cases of neg-
ative histopathology, stable clinical conditions for at least 6 monthsFIGURE 1. Example of target and reference region delineations o
of the different analytical approaches for tumor and background
SUV, ROI with 50-mm diameter on contralateral side (light blue);
1.6 normal brain uptake (green); SUV16mm, mean uptake within
B, Mihovilovic et al14: background SUV, ROI with 50-mm diamet
SUVmean in a 10-mm ROI around the voxel the highest uptake (g
et al22: approach similar to A), with the only difference of SUVmax
D, Pöpperl et al21: SUVmax, the voxel with the maximum FET upta
70% isocontour ROIs (green, 80% ROI shown); background SUV
contralateral hemisphere (blue, 80% ROI shown). E, Crescent sha
positioned on 3 transaxial slices on the level of the basal ganglia (
Rapp et al.22 Additionally, a 90% isocontour covering the lesion o
used (not shown).
© 2019 The Author(s). Published by Wolters Kluwer Health, Inc.(with no treatment changes within this time period), or stabilization/
regression of the contrast-enhancing lesions at follow-upMRI (at least
4 weeks following initial assessment), respectively.24
Statistical Analysis
Descriptive statistics for patient characteristics were reported
as mean ± SD, median, and range. t Test for independent samples
was used to compare means between clinical conditions. The diag-
nostic performances of the different analytical approaches were
assessed by calculating and comparing the area under the receiver
operating characteristic (ROC) curves (R Package pROC version
1.13.0 [R Foundation for Statistical Computing, Vienna, Austria],
according to DeLong et al25). Optimal cutoff values for the various
TBR measures indicative of true progression (as opposed to PsP)
were determined by using the Youden index for cutoff selection.
All statistical tests were performed 2-sided, and P < 0.05 was con-
sidered to indicate statistical significance.RESULTS
Patient Characteristics
This retrospective study included 36 subjects with histologically
proven GBM. Patients underwent imaging while receiving first-line
treatment consisting of temozolomide-based radiochemotherapy
with adjuvant temozolomide according to Stupp et al26 (n = 34),f the different analytical approaches. Shown is an example
SUV derivation in patient 19. A, Kebir et al13: background
SUVmean of the tumor, mean value of ROI with threshold
16-mm ROI centered on maximal tumor uptake (yellow).
er on contralateral side (light blue); SUV10mm of the tumor,
reen); SUVmax, voxel with the highest uptake (red). C, Rapp
being the voxel with the highest amino acid uptake (red).
ke (red). SUV80% and SUV70%, mean uptake within 80% and
, mean of the 70% and 80% isocontour ROI mirrored to the
ped: background SUV, mean uptake of crescent-shaped VOI
blue); tumor SUVmean (green) and SUVmax (red), identical to
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Clinical Nuclear Medicine • Volume 44, Number 9, September 2019 Different FET PET Approaches in Late PsPor after radiotherapy alone (n = 2), respectively. Individual patient
data are shown in Table 2.
Diagnosis of True Tumor Progression Versus Late PsP
Diagnosis of true tumor progression versus late PsP was es-
tablished by histological analysis of surgical tumor samples in 16
of 36 patients and by clinical and radiological examination in the re-
mainder. In total, true tumor progression was diagnosed in 28 of 36
cases and late PsP in the remaining 8 subjects (Fig. 2).
Imaging Results
All TBR measures were significantly higher in patients with
true tumor progression as compared with late PsP regardless of the
semiquantitative approach applied (all P ≤ 0.002, respectively).
Values for TBR obtained using the different analytical strategies
are given in Table 3 (mean ± SD).
The ROC analysis yielded roughly comparable areas under
the curve (AUCs) for each of the different approaches for the differ-
entiation between true glioma progression and late PsP, ranging
from 0.80 (TBRmean derived according to Kebir et al,
13 Rapp et al22)
to 0.88 (TBRmean80% derived according to Pöpperl et al21). The
ROC AUC differences among the 10 methods were not statistically
significant (all P > 0.05; Table 4). However, it is interesting to note
that TBR outcome measures relying on liberal tumor definitions
(ie, TBRmean using a TBR threshold >1.6 in the approaches by Kebir
et al,13 Rapp et al,22 and crescent shaped; AUC = 0.80–0.83) or on
fixed-size nonanatomical tumor definitions (ie, TBR16mm and
TBR10mm byKebir et al
13 andMihovilovic et al14; AUC= 0.81–0.82)
provided the lowest ROCAUCvalues. Compared with the aforemen-
tioned parameters and within each of the parameter sets relying on
the same reference region, the diagnostic performance of TBRmax
was consistently higher (Rapp et al,22 Mihovilovic et al,14 and cres-
cent shaped, AUC = 0.84–0.86), which tended to be slightly
outperformed by TBR measures relying on multiple voxels with the
highest uptake (TBR70%, TBR80%, and TBR90% according to Pöpperl
et al21 and the crescent-shaped method, ROC AUC = 0.85–0.88).
Optimum cutoff values as well as the corresponding values
for sensitivity and specificity for all contemplated TBR outcomeFIGURE 2. Flowchart of participant selection and outcomes. Betw
(22 males and 14 females; aged 24–75 years; mean age, 54 ± 14
previously undergone external beam radiation (end of radiation >
referred to PET due to MRI-based suspicion of recurrence/progres
Diagnosis of true tumor progression versus late PsP was establishe
16 of 36 patients and by clinical and radiological examination in
diagnosed in 28 of 36 cases and late PsP in the remaining 8 subje
recurrence with ROC AUCs ranging from 0.80 to 088.
© 2019 The Author(s). Published by Wolters Kluwer Health, Inc.measures are shown in Supplemental Table 1 (Supplemental Digital
Content 1, http://links.lww.com/CNM/A202).DISCUSSION
The value of 18F-FET PETas an easy-to-read and robust tool
in glioma imaging is well acknowledged and has been demonstrated
over many years.23,24 However, the methodology is yet to be harmo-
nized. Depending on the history and preference of the respective
clinical site, differences exist in imaging protocols (dynamic vs
static acquisition) as well as definition of both the tumor and the
normal brain reference regions. Previous studies have reported on
the influence of reference region definition16 and data processing
at different imaging centers.17 In the present study, we compared
10 different analytic approaches (ie, relying on 7 and 3 different
methods for tumor and normal brain reference region definition,
respectively) in the setting of suspected late PsP in GBM using
static 18F-FET PET. In the present cohort, all approaches achieved
roughly comparable performance in the differentiation of nonspe-
cific treatment-related changes from true tumor progression with
ROC AUC ranging between 0.80 and 0.88, thus confirming the
general suitability of 18F-FET PET for the definition of biologically
active tumor.
Noteworthy, TBR outcomemeasures relying on liberal tumor
definitions (ie, TBRmean using aTBR threshold >1.6;AUC=0.80–0.83)
or on fixed-size nonanatomical tumor definitions (ie, TBR16mm and
TBR10mm; AUC = 0.81–0.82) yielded the lowest ROC AUC values
observed. This may be explained by the fact that the aforemen-
tioned threshold was defined on primary brain tumors (low and
high grade),4 while the distinction between true tumor progression
and PsP is complicated by benign treatment-related changes with
increased FET uptake (among others, including technical factors)
that necessitate higher cutoff values.8,27 Likewise, fixed-size
nonanatomical tumor definitions are expected to include nonneoplastic
tissue like normal tissue, scar tissue or even cerebrospinal fluid
spaces. This observation underlines that need for using suitable
thresholds for a given clinical situation and/or proper anatomical tu-
mor region definition.een April 2010 and August 2016, 36 consecutive patients
years) with a history of GBM were included. All patients had
12 weeks prior to presentation in all cases) and were now
sion of GBM according to RANO working group criteria.
d by histological analysis of surgical tumor samples in
the remainder (20/36). In total, true tumor progression was
cts. PET robustly differentiated late PsP from true tumor
www.nuclearmed.com 699
TABLE 3. Results of Regional Analyses (Mean ± SD Over All Patients)
Parameter PsP (n = 8) Tumor Progression (n = 28)
Kebir et al13 TBRmean
1 2.08 ± 0.18 2.37 ± 0.30
TBR16mm 2.31 ± 0.35 2.89 ± 0.53
Rapp et al22 TBRmean
1 2.08 ± 0.18 2.37 ± 0.30
TBRmax
2 3.22 ± 0.62 4.43 ± 1.01
Mihovilovic et al14 TBR10mm 2.70 ± 0.53 3.56 ± 0.79
TBRmax
2 3.22 ± 0.62 4.43 ± 1.01
Pöpperl et al21 TBR70% 2.47 ± 0.37 3.48 ± 0.81
TBR80% 2.72 ± 0.39 3.77 ± 0.86
TBRmax 3.11 ± 0.47 4.27 ± 0.95
“Crescent shaped” TBRmean 2.06 ± 0.15 2.36 ± 0.26
TBR90% 2.84 ± 0.33 3.86 ± 0.97
TBRmax 3.01 ± 0.38 4.09 ± 1.00
TBR is SUVof target region divided by SUVof reference region; for region definition, see Table 1.
Superscripts 1 and 2 denote pairs of identical analytical approaches.
TABLE 4. ROC AUCs of the TBR Outcome Measures






















All approaches yielded comparable AUC with all P > 0.05, respectively. TBR is
SUV of target region divided by SUV of reference region; for region definition, see
Table 1.
Superscripts 1 and 2 denote pairs of identical analytical approaches.
Kertels et al Clinical Nuclear Medicine • Volume 44, Number 9, September 2019Thus, given the use of different scanners for data acquisition
as well as different reconstruction software and parameters, cutoffs
for the definition of vital tumor need to be confirmed individually
for each imaging center and clinical situation.
In line with this, approaches utilizing SUVmax (ROC
AUC = 0.84–0.86) as an imaging analog of a “punch biopsy”
targeting the most suspicious lesion part were consistently superior
to aforementioned approaches, although not reaching statistical sig-
nificance. However, methods relying on SUVmax are generally
more susceptible to the confounding influence of PET system per-
formance, image reconstruction, and noise (eg, spatial resolution,
reconstruction-induced noise enhancement, postfiltering) than any
average-basedmethod employing larger regions. As a consequence,
we and others21 also used isocontour approaches includingmultiple
voxels with the highest 18F-FET uptake. In fact, in direct compari-
son to TBRmax, TBR70%, TBR80%, and TBR90% tended to perform
slightly better (ROC AUC = 0.85–0.88).
It is important to note that the definition of the normal brain
reference region is just as important as the definition of the tumor
target regions. In a recent publication, Unterrainer et al16 discussed
the need of a consistent method of background activity assessment
and proposed a crescent-shaped background VOI as a reproducible
approach for methodological standardization.16 We also employ a
similar approach in clinical routine using clear instructions for
definition of a large, anatomically defined reference region (see Ma-
terials and Methods), which usually also incorporates coregistration
with MRI (if available). This is done to reduce noise, increase repro-
ducibility, and avoid potential pitfalls of reference region definition
(eg, inclusion of structural changes due to atrophy, trauma, or ische-
mia) that can hardly be avoided when using fixed-size nonanatomical
reference regions or strictly mirrored tumor regions as reference re-
gions. In addition, a method for definition of tumor and normal brain
tissue should be advocated for all clinical situations.
Although various approaches for the differentiation of late
PsP from true tumor progression proved feasible in the current
study, harmonization of PETanalysis is of high relevance, in partic-
ular with regard to future prospective, multicenter trials to foster ev-
idence of the added value of amino acid–based PET in glioma or
when using 18F-FET PET for treatment decisions and planning. Fu-
ture guidelines should recommend standard approaches for the im-
aging protocols (eg, dynamic vs static acquisition, reconstruction
methods, use of resolution recovery, etc) and analysis method
(method of region definition) to facilitate comparisons between700 www.nuclearmed.comdifferent sites, reduce sources of errors, and eventually establish
an optimal study setup for future research. Based on the present re-
sults and aforementioned theoretical reasoning, the use of an
isocontour including multiple voxels with the highest uptake (eg,
SUV80% or SUV90%) and a large, anatomically defined reference re-
gion (eg, crescent shaped) seems to be particularly advisable. The
latter recommendation may apply to clinical settings analogous
not only to the present setting (ie, decision on the presence or ab-
sence of viable tumor tissue) but also to the delineation of
tumor extent.
Limitations of this study include its small sample size and
its retrospective nature. Additionally, no dynamic acquisitions
were performed that may provide valuable diagnostic information.28–30
Noteworthy, the TBRvalues (especially TBRmax) in our cohort—while© 2019 The Author(s). Published by Wolters Kluwer Health, Inc.
Clinical Nuclear Medicine • Volume 44, Number 9, September 2019 Different FET PET Approaches in Late PsPaccurately delineating PsP from true tumor progression—turned out to
be considerably higher in our cohort than those previously published
by other groups.13 While a potential influence from treatment-related
changes with associated nonspecific 18F-FET uptake cannot be ex-
cluded, a major contribution to this differencemight be assigned to res-
olution recovery applied during iterative PET reconstruction (TrueX
algorithm). In addition to the commonly used correction factors,
TrueX, on the one hand, improves the visual appearance of the PET im-
age but, on the other hand, results in an overestimation of themaximum
activity observed (especially in small VOIs <12mL31). Thus, the cutoff
values given in Supplemental Table 1 (Supplemental Digital Content 1,
http://links.lww.com/CNM/A202) cannot be easily transferred to
other settings.
CONCLUSIONS
18F-FET PET is a robust tool for detection of late PsP in
GBM, irrespective of the analytical approach. However, methodo-
logical standardization and harmonization to ensure comparability
between different centers would be highly desirable.
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